Shares for Halozyme Therapeutics Inc. surged 12 percent June 5 on news that it will be able to continue clinical trials for its pancreatic cancer treatment, albeit under a revised treatment plan.

In April, the Food and Drug Administration put a clinical hold on Halozyme’s (Nasdaq: HALO) phase 2 study evaluating a drug candidate called PEGPH20 - just few days after the company voluntary stopped patient enrollment in the drug’s clinical trials. An independent data monitoring committee had found discrepancies in the rate of blood clots found in those receiving Halozyme’s drugs versus FDA-approved treatments.

San Diego-based Halozyme said it will begin enrolling patients again once the independent review boards at participating clinical trial sites review and approve the study’s amended protocol.